Javascript must be enabled to continue!
Quercetin enhances apoptotic effect of tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer‐binding protein homologous protein (CHOP)‐death receptor 5 pathway
View through CrossRef
Although tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) has shown efficacy in a phase 2 clinical trial, development of resistance to TRAIL by tumor cells is a major roadblock. We investigated whether quercetin, a flavonoid, can sensitize human ovarian cancer cells to TRAIL. Results indicate that quercetin sensitized cancer cells to TRAIL. The quercetin induced expression of death receptor DR5 but did not affect expression of DR4 in cancer cells. The induction of DR5 was mediated through activation of JNK and through upregulation of a transcription factor CCAAT enhancer‐binding protein homologous protein (CHOP); as silencing of these signaling molecules abrogated the effect of quercetin. Upregulation of DR5 was mediated through the generation of reactive oxygen species (ROS), as ROS scavengers reduced the effect of quercetin on JNK activation, CHOP upregulation, DR induction, TRAIL sensitization, downregulated the expression of cell survival proteins and upregulated the proapoptotic proteins. Furthermore, quercetin enhances TRAIL mediated inhibition of tumor growth of human SKOV‐3 xenograft was associated with induction of apoptosis, activation of caspase‐3, CHOP and DR5. Overall, our data suggest that quercetin enhances apoptotic death of ovarian cancer cells to TRAIL through upregulation of CHOP‐induced DR5 expression following ROS mediated endoplasmic reticulum‐stress.
Title: Quercetin enhances apoptotic effect of tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer‐binding protein homologous protein (CHOP)‐death receptor 5 pathway
Description:
Although tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) has shown efficacy in a phase 2 clinical trial, development of resistance to TRAIL by tumor cells is a major roadblock.
We investigated whether quercetin, a flavonoid, can sensitize human ovarian cancer cells to TRAIL.
Results indicate that quercetin sensitized cancer cells to TRAIL.
The quercetin induced expression of death receptor DR5 but did not affect expression of DR4 in cancer cells.
The induction of DR5 was mediated through activation of JNK and through upregulation of a transcription factor CCAAT enhancer‐binding protein homologous protein (CHOP); as silencing of these signaling molecules abrogated the effect of quercetin.
Upregulation of DR5 was mediated through the generation of reactive oxygen species (ROS), as ROS scavengers reduced the effect of quercetin on JNK activation, CHOP upregulation, DR induction, TRAIL sensitization, downregulated the expression of cell survival proteins and upregulated the proapoptotic proteins.
Furthermore, quercetin enhances TRAIL mediated inhibition of tumor growth of human SKOV‐3 xenograft was associated with induction of apoptosis, activation of caspase‐3, CHOP and DR5.
Overall, our data suggest that quercetin enhances apoptotic death of ovarian cancer cells to TRAIL through upregulation of CHOP‐induced DR5 expression following ROS mediated endoplasmic reticulum‐stress.
Related Results
Abstract 1294: Sensitization of malignant melanomas to TRAIL-induced apoptosis by quercetin
Abstract 1294: Sensitization of malignant melanomas to TRAIL-induced apoptosis by quercetin
Abstract
Skin cancer is among the most commonly-diagnosed cancers with malignant melanoma being associated with the highest rate of metastasis and mortality. In its ...
Transmembrane Cell Signaling by Targeted Ultrasound Contrast Agents in Cancer Therapy
Transmembrane Cell Signaling by Targeted Ultrasound Contrast Agents in Cancer Therapy
In 2016, over 1.68 million people in the United States are expected to be diagnosed with cancer, with approximately 35% of these cases resulting in death making cancer the second m...
IFN‐γ enhances TRAIL‐induced apoptosis through IRF‐1
IFN‐γ enhances TRAIL‐induced apoptosis through IRF‐1
Tumor necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL) is a member of the TNF family and a potent inducer of apoptosis. TRAIL has been shown to effectively limit tum...
Revision of the genus Aspicera Dahlbom, 1842 (Hym.: Figitidae: Aspicerinae)
Revision of the genus Aspicera Dahlbom, 1842 (Hym.: Figitidae: Aspicerinae)
The genus Aspicera Dahlbom (Hymenoptera: Cynipoidea: Figitidae: Aspicerinae) is revised herein. Aspicera has a Holarctic distribution, being here cited for the first time from the ...
Heparan sulfate promotes TRAIL-induced tumor cell apoptosis
Heparan sulfate promotes TRAIL-induced tumor cell apoptosis
Abstract
TRAIL (TNF-related apoptosis-inducing ligand) is a potent inducer of tumor cell apoptosis through TRAIL receptors. While it has been previously pursued as a potential anti...
Abstract 1761: Dual inhibition of HSP27 and FAO as a novel therapeutic strategy for cisplatin-resistant ovarian cancer
Abstract 1761: Dual inhibition of HSP27 and FAO as a novel therapeutic strategy for cisplatin-resistant ovarian cancer
Abstract
Cisplatin is the most commonly employed chemotherapeutic drug for ovarian cancer treatment. However, most ovarian cancer patients experience recurrent cispl...
Targeting TRAIL Agonistic Receptors for Cancer Therapy
Targeting TRAIL Agonistic Receptors for Cancer Therapy
Abstract
Based on preclinical studies demonstrating that tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) exerts a potent and cancer cell–specific pro...
Abstract 5449: Novel seleno-biotin compound inhibits viability of and induces reactive oxygen species (ROS)-mediated apoptosis in ovarian cancer cells
Abstract 5449: Novel seleno-biotin compound inhibits viability of and induces reactive oxygen species (ROS)-mediated apoptosis in ovarian cancer cells
Abstract
Ovarian cancer is one of the most common cancers in women and even with the currently available treatment options, including surgery, radiation, and chemoth...

